EPAM Systems (EPAM) Proxy filing summary
Event summary combining transcript, slides, and related documents.
Proxy filing summary
6 Apr, 2026Executive summary
Annual Meeting scheduled for May 21, 2026, with virtual participation available for shareholders.
Shareholders are encouraged to review proxy materials and annual report before voting.
Voting matters and shareholder proposals
Election of four directors: Balazs Fejes, Eugene Roman, Jill Smart, and Ronald Vargo, all recommended by the board.
Proposal to amend the Certificate of Incorporation to allow stockholders to call a special meeting, recommended for approval.
Ratification of Deloitte & Touche LLP as independent auditor for 2026, recommended for approval.
Advisory vote to approve executive compensation, recommended for approval.
Amendments to increase shares in the 2025 Long Term Incentive Plan (by 4,000,000) and 2021 Employee Stock Purchase Plan (by 650,000), both recommended for approval.
Advisory vote on a shareholder proposal to give shareholders the ability to call a special meeting, recommended against by the board.
Board of directors and corporate governance
Board recommends all director nominees for election at the annual meeting.
Board supports amendments to enhance shareholder rights regarding special meetings.
Latest events from EPAM Systems
- Q1 2026 revenue up 7.6% to $1.4B, with strong EPS and major share repurchases.EPAM
Q1 20267 May 2026 - Accelerating AI-native transformation and targeting double-digit growth with robust margins.EPAM
Investor Day 20264 May 2026 - Proposal 5 adds 4M shares to the equity plan to support talent retention and AI strategy.EPAM
Proxy filing4 May 2026 - Shareholders will vote on seven key proposals, including governance and compensation changes.EPAM
Proxy filing15 Apr 2026 - Board backs governance, compensation, and equity plan changes; opposes lower special meeting threshold.EPAM
Proxy filing6 Apr 2026 - Shareholders will vote on director elections, equity plan amendments, and expanded governance rights.EPAM
Proxy filing26 Mar 2026 - Strong 2025 growth and AI momentum support a robust 2026 outlook for revenue and EPS.EPAM
Q4 202519 Feb 2026 - Q2 revenue down 2% YoY; healthcare strong, margins lower, new $500M buyback approved.EPAM
Q2 20242 Feb 2026 - Q3 revenue and EPS rose, NEORIS acquisition expanded reach, and share buybacks accelerated.EPAM
Q3 202416 Jan 2026